Latest News & Features
Americas
Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers. 11 December 2025
Careers
The lateral hire from Covington & Burling will strengthen the firm's cross-border expertise as the UK and EU markets ‘navigate regulatory and technological shifts’, said the firm. 11 December 2025
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts. 10 December 2025
Asia
The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry. 9 December 2025
Careers
New hires bring “exceptional technical expertise” and a strong track record across biotechnology and pharmaceutical patent matters. 9 December 2025
Americas
Solicitor General urges the US Supreme Court to hear an appeal in its dispute, arguing that a ruling threatens the future of skinny labelling and the availability of lower-cost generics. 9 December 2025
Europe
The firm has added a disputes specialist with experience in pharma, biotech and manufacturing sectors across multiple jurisdictions. 8 December 2025
Americas
As part of a broader bid to remove obstacles to patents, director Squires clarifies how examiners, applicants and practitioners may handle patent subject matter eligibility rejections. 8 December 2025
Americas
A Finnish wearable fitness gadget company has lost its bid to overturn the invalidation of a key patent, with the US Federal Circuit affirming it is abstract under Alice. 5 December 2025
Asia
The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening. 4 December 2025